89bio
Manufacturing · California, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
655 Montgomery St Fl 15, San Francisco, ...Phone Number
(415) 432-9270Website
www.89bio.comRevenue
$384.7 MillionStock Symbol
ETNBIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
3
2
1
1
1
1
About 89bio
89bio is a clinical-stage biopharma company focused on the development and commercialization of therapies for the treatment of non-alcoholic liver and cardio-metabolic diseases. The company is headquartered in San Francisco with operations in Herzliya, Israel.Explore more
89bio Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is 89bio your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once 89bio has new funding data
Earning: See what the market has to say on 89bio recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at 89bio
Check out if 89bio is spiking on competitors!
Website visits: Recent activity has been detected on your website
Check if 89bio has recently received funding, and reach out quickly before it becomes old news!
Click to see if 89bio had a recent Job posting/layoffs
Product Launch: Get notified when 89bio launches new products
89bio, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to 89bio
Compare insights from companies similar to 89bio, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
89bio is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
89bio is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about 89bio.
89bio Tech Stack
A closer look at the technologies used by 89bio
See more technologies
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Person-Based
Person-Based
89bio News & Media
89bio, Inc. Announces Agreement to be Acquired by Roche
– 89bio stockholders to receive up to $20.50 per share in cash, comprised of $14.50 per share in cash at closing and a non-tradeable contingent value right (CVR) to receive up to an aggregate of $6.00 per share in cash; transaction represents total equity value of up to approximately $3.5 billion –89bio to Participate in Upcoming Investor Conferences
SAN FRANCISCO, Aug. 28, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Company’s management will participate in the following investor conferences during the month of September:89bio to Participate in Goldman Sachs 46th Annual Global Healthcare Conference
SAN FRANCISCO, June 04, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Company’s Management will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference on Wednesday, June 11, 2025 at 11:20 AM EDT and participate in one-on-one inves89bio to Participate in Upcoming Investor Conferences
SAN FRANCISCO, May 06, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Company’s Management will participate in the following investor conferences during the month of May:
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding 89bio
Sign Up For FreeTo access detailed company insights
89bio is a clinical-stage biopharma company focused on the development and commercialization of therapies for the treatment of non-alcoholic liver and cardio-metabolic diseases. The company is headquartered in San Francisco with operations in Herzliya, Israel.... Read More
